PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Other EventsItem 8.01 Other Events.
As previously reported, on January 11, 2017, Pulmatrix, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s common stock failed to maintain a minimum market value of publicly held shares (“MVPHS”) of $5,000,000 over the previous 30 consecutive days as required by The NASDAQ Global Market set forth in Listing Rule 5450(b)(1)(C) (the “Rule”). The letter also indicated that the Company had 180 calendar days, or until July 10, 2017, to regain compliance with the Rule. The letter further provided that if, at any time during the 180-day period, the Company’s MVPHS closes at $5,000,000 or more for a minimum of 10 consecutive business days, Nasdaq would provide the Company with written confirmation that it had achieved compliance with the Rule.
On February 1, 2017, the Company received a letter from Nasdaq notifying the Company that for the last 10 consecutive business days, from January 17 through January 31, 2017, the Company’s MVPHS has been $5,000,000 or greater, and therefore, the Company has regained compliance with the Rule and this matter is now closed.
About PULMATRIX, INC. (NASDAQ:PULM)
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease. PULMATRIX, INC. (NASDAQ:PULM) Recent Trading Information
PULMATRIX, INC. (NASDAQ:PULM) closed its last trading session down -0.24 at 4.86 with 52,497,887 shares trading hands.